Savara (SVRA) Stock Rating Lowered by Zacks Investment Research

Savara (NASDAQ:SVRA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday.

According to Zacks, “Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. “

SVRA has been the topic of several other research reports. Canaccord Genuity set a $25.00 price target on shares of Savara and gave the company a “buy” rating in a report on Friday, February 16th. ValuEngine downgraded shares of Savara from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. BidaskClub downgraded shares of Savara from a “hold” rating to a “sell” rating in a research note on Saturday, February 24th. Finally, HC Wainwright initiated coverage on shares of Savara in a research note on Friday, May 25th. They set a “buy” rating and a $22.00 price objective on the stock. Three research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $23.36.

Shares of Savara opened at $10.12 on Wednesday, according to MarketBeat. Savara has a 12-month low of $4.61 and a 12-month high of $17.19. The stock has a market capitalization of $319.54 million, a price-to-earnings ratio of -5.75 and a beta of 0.03. The company has a current ratio of 16.28, a quick ratio of 16.28 and a debt-to-equity ratio of 0.16.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Wednesday, May 9th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.01). equities analysts predict that Savara will post -1.37 EPS for the current fiscal year.

In other news, Director Yuri Pikover acquired 3,734 shares of Savara stock in a transaction that occurred on Thursday, March 29th. The shares were acquired at an average price of $9.00 per share, with a total value of $33,606.00. Following the completion of the purchase, the director now owns 153,734 shares of the company’s stock, valued at approximately $1,383,606. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 6.10% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in SVRA. Consonance Capital Management LP purchased a new position in shares of Savara during the fourth quarter valued at approximately $40,899,000. VHCP Management II LLC purchased a new position in shares of Savara during the fourth quarter valued at approximately $18,691,000. Lyon Street Capital LLC increased its position in Savara by 85.0% during the first quarter. Lyon Street Capital LLC now owns 1,441,984 shares of the company’s stock worth $13,266,000 after purchasing an additional 662,430 shares during the last quarter. Millennium Management LLC increased its position in Savara by 1,161.8% during the first quarter. Millennium Management LLC now owns 522,897 shares of the company’s stock worth $4,811,000 after purchasing an additional 481,456 shares during the last quarter. Finally, BlackRock Inc. increased its position in Savara by 642.4% during the fourth quarter. BlackRock Inc. now owns 499,512 shares of the company’s stock worth $7,412,000 after purchasing an additional 432,225 shares during the last quarter. 40.99% of the stock is currently owned by institutional investors and hedge funds.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Get a free copy of the Zacks research report on Savara (SVRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply